305 related articles for article (PubMed ID: 31644326)
1. Efficacy and safety of cariprazine in the treatment of bipolar disorder.
Saraf G; Pinto JV; Yatham LN
Expert Opin Pharmacother; 2019 Dec; 20(17):2063-2072. PubMed ID: 31644326
[No Abstract] [Full Text] [Related]
2. Cariprazine in the treatment of Bipolar Disorder: A systematic review and meta-analysis.
Pinto JV; Saraf G; Vigo D; Keramatian K; Chakrabarty T; Yatham LN
Bipolar Disord; 2020 Jun; 22(4):360-371. PubMed ID: 31618503
[TBL] [Abstract][Full Text] [Related]
3. Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.
Citrome L
Clin Schizophr Relat Psychoses; 2016; 10(2):109-19. PubMed ID: 27440212
[TBL] [Abstract][Full Text] [Related]
4. Cariprazine for bipolar depression: What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2019 Oct; 73(10):e13397. PubMed ID: 31355510
[TBL] [Abstract][Full Text] [Related]
5. Cariprazine for the Treatment of Bipolar Disorder.
Findlay LJ; El-Mallakh PL; El-Mallakh RS
Perspect Psychiatr Care; 2017 Jul; 53(3):148-155. PubMed ID: 27059102
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial.
Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
Bipolar Disord; 2015 Feb; 17(1):63-75. PubMed ID: 25056368
[TBL] [Abstract][Full Text] [Related]
7. Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials.
Lao KS; He Y; Wong IC; Besag FM; Chan EW
CNS Drugs; 2016 Nov; 30(11):1043-1054. PubMed ID: 27550371
[TBL] [Abstract][Full Text] [Related]
8. Cariprazine for the treatment of bipolar depression: a review.
Ragguett RM; McIntyre RS
Expert Rev Neurother; 2019 Apr; 19(4):317-323. PubMed ID: 30753085
[TBL] [Abstract][Full Text] [Related]
9. Cariprazine in Bipolar Depression and Mania: State of the Art.
Mazza M; Marano G; Traversi G; Carocci V; Romano B; Janiri L
CNS Neurol Disord Drug Targets; 2018; 17(10):723-727. PubMed ID: 30152291
[TBL] [Abstract][Full Text] [Related]
10. Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy.
Citrome L
Adv Ther; 2013 Feb; 30(2):102-13. PubMed ID: 23361832
[TBL] [Abstract][Full Text] [Related]
11. Cariprazine: First Global Approval.
McCormack PL
Drugs; 2015 Nov; 75(17):2035-43. PubMed ID: 26510944
[TBL] [Abstract][Full Text] [Related]
12. Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study.
Earley W; Burgess MV; Rekeda L; Dickinson R; Szatmári B; Németh G; McIntyre RS; Sachs GS; Yatham LN
Am J Psychiatry; 2019 Jun; 176(6):439-448. PubMed ID: 30845817
[TBL] [Abstract][Full Text] [Related]
13. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability.
Citrome L
Expert Opin Drug Metab Toxicol; 2013 Feb; 9(2):193-206. PubMed ID: 23320989
[TBL] [Abstract][Full Text] [Related]
14. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial.
Sachs GS; Greenberg WM; Starace A; Lu K; Ruth A; Laszlovszky I; Németh G; Durgam S
J Affect Disord; 2015 Mar; 174():296-302. PubMed ID: 25532076
[TBL] [Abstract][Full Text] [Related]
15. Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies.
Earley W; Durgam S; Lu K; Debelle M; Laszlovszky I; Vieta E; Yatham LN
J Affect Disord; 2017 Jun; 215():205-212. PubMed ID: 28343051
[TBL] [Abstract][Full Text] [Related]
16. Cariprazine-induced mania: A case series report.
Pons-Cabrera MT; Palacios-Garrán R; Tardón-Senabre L; Fernández-Plaza T; Marco-Estrada O; Madero S; Anmella G; Colomer L; Druetta M; Giménez-Palomo A; Navarro-Cortés L; Sagué-Vilavella M; Sánchez-Sierra C; Verdolini N; Catalan R; Bioque M; Goikolea JM; Vieta E; Pacchiarotti I
Bipolar Disord; 2022 Jun; 24(4):457-460. PubMed ID: 34797609
[TBL] [Abstract][Full Text] [Related]
17. The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study.
Ketter TA; Sachs GS; Durgam S; Lu K; Starace A; Laszlovszky I; Németh G
J Affect Disord; 2018 Jan; 225():350-356. PubMed ID: 28843918
[TBL] [Abstract][Full Text] [Related]
18. Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies.
McIntyre RS; Suppes T; Earley W; Patel M; Stahl SM
CNS Spectr; 2020 Aug; 25(4):502-510. PubMed ID: 31576791
[TBL] [Abstract][Full Text] [Related]
19. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
Demyttenaere K; Detraux J; Racagni G; Vansteelandt K
CNS Drugs; 2019 Jun; 33(6):549-566. PubMed ID: 31065941
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled studies.
Earley W; Durgam S; Lu K; Laszlovszky I; Debelle M; Kane JM
Int Clin Psychopharmacol; 2017 Nov; 32(6):319-328. PubMed ID: 28692485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
